{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959902",
  "id": "02959902",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0832",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwrlpwdpmwt3.pdf",
  "summary": "- **Second confirmed complete response (CR)** recorded in the ACCENT trial evaluating narmafotinib (FAK inhibitor) + chemotherapy for advanced pancreatic cancer.  \n- **Advanced pancreatic cancer CRs are extremely rare** (e.g., 1 CR in 431 patients in prior seminal study).  \n- **Trial details**: Phase 1b/2a, single-arm, open-label (55 patients enrolled); primary endpoints include Objective Response Rate (ORR) and Duration on Trial (DOT).  \n\n*No material trading or capital markets actions identified (clinical update only).*",
  "usage": {
    "prompt_tokens": 1269,
    "completion_tokens": 121,
    "total_tokens": 1390,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T22:58:30.156447"
}